How Technology and Development Partners Can Accelerate Next-Generation ADC Payload Innovation

Why Is ADC Payload Development Becoming More Partner-Dependent?

The next generation of ADC payloads is expanding beyond established tubulin and topoisomerase I inhibitors toward mechanisms including N-myristoyltransferase inhibitors, targeted protein degraders, molecular glues, RNA splicing modulators, and immune-activating approaches.

At the same time, dual- and multi-payload ADCs are being investigated as a way to address resistance and tumor heterogeneity through complementary mechanisms of action.

These approaches introduce questions that may fall outside the established capabilities of an internal ADC team:

• Can the proposed mechanism generate sufficient activity at the intracellular exposure achievable through an ADC?
• Which tumor types or resistance states are most likely to respond?
• Can the payload be modified without losing its intended biological activity?
• Is the payload compatible with the chosen linker, attachment site, and release mechanism?
• Can both payloads in a dual-payload ADC reach their sites of action at pharmacologically relevant concentrations?
• Which assays and models can predict efficacy, toxicity, and resistance more reliably?
• Can the payload-linker system be synthesized, characterized, and manufactured reproducibly?
• What containment, analytical, and quality controls will be required as the program advances?

External partners can provide specialized technologies and experience across these areas. However, developers increasingly need more than access to an isolated service. They need evidence that a partner understands how its contribution affects the performance of the complete ADC.

Where Can Payload Technology Providers Create the Most Value?

Payload technology providers may offer proprietary warheads, novel mechanisms, screening platforms, or linker-payload systems that allow developers to explore biology beyond established cytotoxic classes.

Their value is strongest when the platform is supported by a clear biological and translational rationale.

A differentiated mechanism alone does not establish that a payload is suitable for ADC delivery. Developers need to understand its required intracellular concentration, susceptibility to efflux, membrane permeability, metabolic stability, release requirements, and potential on-target effects in healthy tissue.

Technology providers can strengthen the case for their platforms by demonstrating:

• Why targeted delivery improves the profile of the underlying mechanism
• Which tumor vulnerabilities or resistance mechanisms the payload addresses
• How activity compares with relevant established payloads
• Whether the mechanism remains active in resistant or heterogeneous models
• How structural modification affects potency and developability
• Which linker and release strategies are compatible with the payload
• Whether useful pharmacodynamic or response biomarkers are available
• How the payload behaves when incorporated into a complete ADC

This moves the conversation beyond novelty and toward development relevance. It also gives prospective partners clearer evidence that the technology can address a defined limitation in their pipeline.

How Can Medicinal and Synthetic Chemistry Partners Support Payload Optimization?

Novel payload discovery frequently requires developers to balance competing properties. A compound may demonstrate compelling biochemical activity but lack the solubility, stability, functional handle, or physicochemical profile needed for successful conjugation.

Specialized medicinal and synthetic chemistry partners can help convert an interesting mechanism into a more viable ADC payload by exploring the relationship between structure, potency, and developability.

Important areas of support include:

• Designing analogs with suitable conjugation handles
• Preserving activity following linker attachment
• Improving solubility and reducing excessive hydrophobicity
• Modifying membrane permeability and bystander potential
• Evaluating susceptibility to metabolic degradation or drug efflux
• Developing scalable and reproducible synthetic routes
• Establishing structure-activity and structure-property relationships
• Generating sufficient material for comparative testing and preclinical studies

The objective should not be to maximize potency as an isolated endpoint. It should be to identify a property profile capable of delivering sufficient tumor-selective activity while supporting conjugation, analytical control, and future manufacturing.

This requires close collaboration between chemists, biologists, pharmacologists, and ADC engineers. Partners able to connect these disciplines are better positioned to help developers avoid optimizing a compound that cannot succeed as part of a complete conjugate.

What Do Developers Need From Payload CDMOs?

The transition from discovery-scale material to a controlled development and manufacturing process can expose weaknesses that were not apparent during early research.

ADC payloads may require complex multistep synthesis, specialized containment, sensitive purification methods, and strict impurity control. Novel payloads can introduce additional uncertainty because their process behavior, degradation pathways, and analytical profiles may not yet be fully understood.

Payload CDMOs can help developers address these risks through capabilities including:

• Route scouting and process development
• High-potency compound handling and containment
• Payload and linker-payload synthesis
• Impurity identification and control
• Analytical method development and validation
• Stability and storage assessments
• Technology transfer and scale-up
• GMP manufacturing and supply-chain planning
• Coordination between payload, linker, antibody, and conjugation activities

For developers, the key question is not simply whether a CDMO can manufacture a payload. It is whether the partner can maintain control as the program moves between scales, sites, and development stages.

That requires early attention to critical quality attributes, process sensitivity, raw-material availability, analytical comparability, and the interaction between payload quality and downstream conjugation performance.

CDMOs that engage early can also help teams identify synthetic, safety, or scale-up liabilities before those issues affect clinical timelines.

Why Must Partners Understand the Complete Linker-Payload System?

The payload does not function independently from the linker, conjugation method, or antibody. A promising payload can be undermined by premature release, insufficient intracellular liberation, excessive hydrophobicity, aggregation, rapid clearance, or poor access to its site of action.

Partners working on payload technologies must therefore understand how their contribution interacts with:

• Linker stability in circulation
• Cleavage or release within the target environment
• Drug-to-antibody ratio
• Conjugation-site selection
• ADC homogeneity
• Intracellular trafficking
• Payload permeability
• Bystander activity
• Pharmacokinetics
• Formulation and storage stability

This systems-level understanding is particularly important for novel mechanisms. A release strategy developed for a conventional cytotoxic payload may not be appropriate for a degrader, immune agonist, or RNA splicing modulator.

Each mechanism may require a different intracellular location, release rate, or active chemical species. Applying an established linker-payload template without considering those requirements could produce misleading conclusions about the mechanism itself.

The most useful partners will be able to explain not only whether their technology works, but under which biological and engineering conditions it is most likely to work.

How Can CROs Improve Payload Selection and Translation?

One of the most persistent challenges in ADC development is determining whether encouraging preclinical activity will translate into an acceptable clinical therapeutic window.

Basic cell-line potency is rarely sufficient to answer this question. Developers must understand how antigen expression, internalization, trafficking, release, payload sensitivity, tumor heterogeneity, resistance, and systemic exposure influence the observed response.

Specialized CROs can support more informative payload decisions by providing:

• Comparative in vitro profiling across payload classes
• Mechanistic and target-engagement assays
• Cytotoxicity and bystander-effect assessments
• Drug-efflux and resistance modeling
• Combination and synergy studies
• Patient-derived xenograft testing
• Organoid and human tissue-based systems
• Exposure-response and pharmacodynamic analysis
• Toxicology and safety profiling
• Biomarker development
• Bioanalytical and DMPK support

The value of these services depends on how well the models reflect the intended clinical question.

For example, a developer comparing two payloads may need more than an efficacy ranking in a sensitive model. The decision may require evidence from resistant models, mixed-antigen systems, non-proliferating cell populations, or models that reproduce clinically relevant expression and trafficking behavior.

CROs can differentiate their offering by helping clients choose the right experimental system for the decision being made, rather than simply offering the broadest possible panel of assays.

What Additional Challenges Do Dual-Payload ADCs Create?

Dual-payload ADCs increase the need for coordinated development support because two mechanisms, two payloads, and potentially two release strategies must function within one construct.

The combination must be biologically justified. It should address complementary vulnerabilities, established resistance mechanisms, or distinct tumor-cell populations rather than adding complexity without a clear advantage.

Development partners may need to help optimize:

• Payload pairing and mechanistic rationale
• Relative potency
• Payload ratio
• Total drug-to-antibody ratio
• Linker compatibility
• Coordinated or sequential release
• Intracellular localization
• Hydrophobicity and aggregation
• Analytical characterization
• In vivo exposure
• Overlapping toxicity
• Process reproducibility and scale-up

A central challenge is demonstrating that both payloads make a meaningful contribution. If one mechanism dominates at the achievable exposure, the second payload may increase analytical, manufacturing, and toxicological complexity without improving efficacy.

Technology providers and research partners can add value by developing experimental frameworks that distinguish additive, synergistic, and redundant activity. CDMOs can then help translate the selected design into a controllable and reproducible product.

What Should ADC Developers Look for in a Payload Partner?

The right partner will depend on the scientific question, development stage, and internal capabilities of the ADC developer. Nevertheless, several criteria can help teams assess potential collaborators.

Relevant Scientific Expertise

The partner should understand the biology and chemistry of the specific payload class rather than relying exclusively on experience with established ADC mechanisms.

Integrated Problem-Solving

The organization should be able to explain how its work affects the wider ADC, including linker selection, conjugation, release, pharmacology, safety, and manufacturability.

Decision-Quality Data

Studies should be designed around clear development decisions, with suitable controls, comparators, and models.

Flexibility

Novel and dual-payload programs may not fit standard workflows. Partners should be able to adapt methods and development strategies to the needs of the individual program.

Translational Awareness

The partner should distinguish between early proof of concept and evidence that supports clinical progression.

Analytical and Process Control

Payload and linker-payload quality must remain measurable and reproducible as the program advances.

Scalable Capabilities

Developers should understand whether the partner can continue supporting the program through later preclinical, clinical, and commercial stages, or facilitate a controlled technology transfer.

Collaborative Transparency

Early disclosure of limitations, negative results, and technical risks can be more valuable than selectively presenting positive findings.

How Can Solution Providers Differentiate in a Growing ADC Market?

As the ADC field expands, solution providers face increasing competition. Broad claims around speed, quality, or end-to-end capabilities may not be enough to demonstrate relevance to payload-focused development teams.

Providers can differentiate by showing how their expertise solves a defined scientific or development challenge.

This could include evidence of how they:

• Improve the developability of a difficult payload
• Identify combinations that overcome a specific resistance mechanism
• Reduce uncertainty when selecting between linker-payload designs
• Develop human-relevant models for translational assessment
• Control highly potent or structurally complex payloads at scale
• Address analytical challenges in dual-payload ADCs
• Integrate discovery chemistry with later manufacturing requirements
• Help developers determine when a new payload mechanism offers genuine value

The strongest commercial message will connect a capability to the decisions and risks faced by ADC developers. Providers that communicate in this way can position themselves as scientific collaborators rather than interchangeable vendors.

Building More Effective ADC Payload Partnerships

The growing diversity of ADC payload strategies is placing greater demands on discovery, medicinal chemistry, biology, engineering, translational science, toxicology, and manufacturing teams.

External partners can help fill capability gaps, introduce differentiated technologies, and reduce development risk. However, the success of these collaborations will depend on whether the partner can connect its specialized expertise to the behavior and requirements of the complete ADC.

Payload providers must demonstrate more than novelty. CROs must generate evidence that answers the relevant development question. Medicinal chemistry partners must balance activity with conjugation and developability. CDMOs must translate complex payload-linker systems into controlled, scalable, and compliant processes.

As novel and multi-payload ADCs progress, the most valuable partnerships will be those that combine specialized capabilities with a shared understanding of biological rationale, therapeutic window, translational predictability, and manufacturability.

Connect With the ADC Payload Development Community

The 3rd ADC Payload Summit is the only industry-focused summit dedicated specifically to ADC payload discovery and development. It brings together leaders across payload chemistry, medicinal chemistry, biology, engineering, translational science, toxicology, and ADC R&D to advance established and next-generation payload mechanisms.

For payload technology providers, CDMOs, CROs, and other specialized partners, the summit provides an opportunity to understand the scientific and operational challenges shaping development decisions, demonstrate relevant capabilities, and build relationships with the teams advancing ADC pipelines.

Join focused discussions covering novel payload mechanisms, dual-payload engineering, linker-payload integration, resistance, predictive preclinical modeling, therapeutic-window optimization, and clinical translation.

Explore the 2026 ADC Payload Agenda

Discover the Partnership Opportunity

Register for the ADC Payload Summit